EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Transgene's enterprise value is €118.72 Mil.
Transgene's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €1.18 Mil. Therefore, Transgene's EV-to-Revenue for today is 100.27.
The historical rank and industry rank for Transgene's EV-to-Revenue or its related term are showing as below:
XPAR:TNG'
s EV-to-Revenue Range Over the Past 10 Years
Min: 8.63 Med: 66.02 Max: 164.42
Current: 100.26
During the past 13 years, the highest EV-to-Revenue of Transgene was 164.42. The lowest was 8.63. And the median was 66.02.
XPAR:TNG's EV-to-Revenue is ranked worse than 84.19% of 1037
companies
in the Biotechnology industry
Industry Median: 8.14
vs XPAR:TNG: 100.26
As of today (2024-05-08), Transgene's stock price is €1.32.
Transgene's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.01. Therefore, Transgene's PS Ratio for today is 110.00.
Transgene EV-to-Revenue Historical Data
The historical data trend for Transgene's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Transgene's EV-to-Revenue
For the Biotechnology subindustry, Transgene's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgene's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgene's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Transgene's EV-to-Revenue falls into.
Transgene's current Enterprise Value is €118.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Transgene's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €1.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgene's share price for today is €1.32.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgene EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Transgene's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XPAR:TNG has been successfully added to your 